| Literature DB >> 28395335 |
Aymara Mas1, Lauren Prusinski1, Qiwei Yang1, Patricia Diaz-Gimeno2, Lelyand Stone1, Michael P Diamond1, Carlos Simón3, Ayman Al-Hendy1.
Abstract
Regulation of myometrial functions during pregnancy has been considered the result of the integration of endocrine and mechanical signals. Nevertheless, uterine regeneration is poorly understood, and the cellular source within the gravid uterus is largely unexplored.In this study, we isolated and quantified the myometrial stem cells (MSC) population from pregnant female Eker rat uteri, by using Stro1/CD44 surface markers. We demonstrated that prior parity significantly increased the percentage of Stro1+/CD44+ MSC because of injured tissue response. Interestingly, we established that Stro1+/CD44+ MSC respond efficiently to physiological cues when they were treated in vitro under different dose-dependent pregnant rat serum.Previous studies reveal strong regulatory links between O2 availability and stem cell function. Based on these premises, cell proliferation assays showed that isolated Stro1+/CD44+ MSC possess a higher proliferative rate under hypoxic versus normoxic conditions. We also detected a total of 37 upregulated and 44 downregulated hypoxia-related genes, which were differentially expressed in Stro1+/CD44+ MSC, providing an alternative approach to infer into complex molecular mechanisms such as energy metabolism, inflammatory response, uterine expansion, and/or remodeling.Since these cells preferentially grow under low oxygen conditions, we propose that the increase of the rat uterus during pregnancy involves myometrial oxygen consumption, thereby enhancing MSC proliferation. Moreover, pregnancy-induced mechanical stretching results in hypoxic conditions, ultimately creating an environment that promotes stem cell proliferation and further uterine enlargement, which is essential for a successful pregnancy. In summary, all of these data support that rat Stro1+/CD44+ MSC contribute to uterine enlargement during pregnancy.Entities:
Keywords: Stro1/CD44; hypoxia; myometrial stem cells; pregnancy
Mesh:
Substances:
Year: 2017 PMID: 28395335 PMCID: PMC5803774 DOI: 10.1095/biolreprod.116.143461
Source DB: PubMed Journal: Biol Reprod ISSN: 0006-3363 Impact factor: 4.285
Figure 1.Parity responsiveness in Stro1+/ CD44+ myometrial stem cell population. (A) FACS analysis demonstrating the percentage of Stro1+/CD44+ myometrial stem cells in nulliparous versus multiparous nonpregnant rats. Unpaired t test was used for statistical analysis *P < 0.05. Values are expressed as mean ± SEM for four independent animals per condition. (B) Timeline of the experimental methods: female rats at 3 months of age were naturally mated with fertile males. Pregnant female rats were identified by vaginal plugs. Tissue was collected during different time points of pregnancy (D0, D5, D15, D20) for several purposes. (C) Quantification of Stro1+/CD44+ myometrial stem cells from Eker [Long Evans; Tsc-2(Ek/+)] pregnant rats at days 0, 5, 15, 20 of pregnancy (n = 16). Two-tailed Student t test was used for statistical analysis *P < 0.05.
Figure 2.Comparison of cell proliferation rates under pregnant rat serum treatment and low oxygen conditions. (A) Proliferation rates of Stro1+/CD44+ myometrial stem cells under dose-dependent pregnant rat serum treatment, 5% (full concentration). Values are expressed as mean ± SEM for four independent animals per condition. (B) Proliferation rates of Stro1+/CD44+ myometrial stem cells under dose-dependent pregnant rat serum treatment 2.5% (half concentration). Values are expressed as mean ± SEM for four independent animals per condition. (C) Proliferation rates in hypoxia versus normoxia cultured myometrial cells: primary (–/–) and stem (+/+). Unpaired t test was used for statistical analysis *P <0.05. Values are expressed as mean ± SEM for four independent animals per condition.
List of genes up- and downregulated in the hypoxia versus normoxia-grown Stro-1+/CD44+ myometrial stem cells
| Upregulated genes | Full gene name | Fold change |
|
| Insulin like growth factor binding protein 3 precursor | 46,650 |
|
| Matrix metalloproteinase 9 precursor | 17,915 |
|
| Urokinase-type plasminogen activator precursor | 7,568 |
|
| Macrophage migration inhibitory factor | 6,721 |
|
| Recombining binding protein suppressor of hairless-like protein | 4,415 |
|
| Angiopoietin-related protein 4 | 3,939 |
|
| Protein NDRG1 | 3,878 |
|
| Adrenomedullin proadrenomedullin N-20 terminal peptide | 3,302 |
|
| ERO1-like protein alpha precursor | 3,302 |
|
| Solute carrier family 2, facilitated glucose transporter member 1 | 2,467 |
|
| Phosphoglycerate kinase 1 | 2,279 |
|
| Plasminogen activator inhibitor 1 precursor | 1,829 |
|
| Carbonic anhydrase 9 precursor | 1,712 |
|
| Solute carrier family 2, facilitated glucose transporter member 3 | 1,674 |
|
| Monocarboxylate transporter 4 | 1,606 |
|
| 6-Phosphofructokinase, liver type | 1,563 |
|
| L-lactate dehydrogenase A chain | 1,496 |
|
| Ankyrin repeat domain-containing protein 37 | 1,485 |
|
| Placental growth factor | 1,453 |
|
| Glucose-6-phosphate isomerase | 1,445 |
|
| Pyruvate dehydrogenase kinase, isozyme 1 precursor | 1,435 |
|
| Triosephosphate isomerase 1 | 1,423 |
|
| Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 | 1,372 |
|
| 6-Phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3 | 1,246 |
|
| Hexokinase 2 | 1,223 |
|
| Phosphoglycerate mutase 1 | 1,22 |
|
| BCL2/adenovirus E1B interacting protein 3 | 1,186 |
|
| 6-Phosphofructokinase type C | 1,163 |
|
| Egl nine homolog 1 | 1,106 |
|
| Uncharacterized protein | 1,096 |
|
| Proto-oncogene c-Fos | 1,072 |
|
| Protein disulfide-isomerase | 1,071 |
|
| Fructose-bisphosphate aldolase A | 1,061 |
|
| Serine/threonine-protein kinase pim-1 | 1,057 |
|
| Immediate early response 3 | 1,050 |
|
| DNA damage inducible transcript 4 protein | 1,032 |
|
| Glycogen [starch] synthase, muscle | 1,022 |
|
| Thioredoxin interacting protein | –4,769 |
|
| Protein BTG1 | –2,653 |
|
| Endothelin 1 | –2,272 |
|
| Eukaryotic translation initiation factor 4E binding protein 1 | –2,168 |
|
| Early growth response protein 1 | –2,075 |
|
| Cellular tumor antigen p53 | –2,007 |
|
| Hypoxia inducible factor 3-alpha | –2,001 |
|
| Ornithine decarboxylase 1 | –1,998 |
|
| DNA-(apurinic or apyrimidinic site) lyase DNA-(apurinic or apyrimidinic site) lyase, mitochondrial | –1,892 |
|
| Beta-2-microglobulin | –1,785 |
|
| Lysosomal protective protein precursor | –1,703 |
|
| Heme oxygenase 1 | –1,555 |
|
| COP9 signalosome complex subunit 5 | –1,538 |
|
| Voltage dependent anion-selective channel protein 1 | –1,523 |
|
| Upstream stimulatory factor 2 | –1,513 |
|
| Alpha-enolase | –1,500 |
|
| Hypoxia inducible factor 1 alpha | –1,488 |
|
| Cyclin dependent kinase inhibitor 2A | –1,455 |
|
| 6-Phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 4 | –1,443 |
|
| Protein-lysine 6-oxidase | –1,425 |
|
| Max interacting protein 1 | –1,413 |
|
| Adenosine A2b receptor | –1,409 |
|
| Vascular endothelial growth factor A | –1,409 |
|
| Hepatocyte growth factor receptor precursor | –1,353 |
|
| Egl nine homolog 2 | –1,348 |
|
| Nuclear factor NF-kappa-B p105 subunit nuclear factor NF-kappa-B p50 subunit | –1,330 |
|
| DnaJ homolog subfamily C member 5 | –1,317 |
|
| Annexin A2 | –1,294 |
|
| Actin, cytoplasmic 1 Actin, cytoplasmic 1, N-terminally processed | –1,263 |
|
| Phosphoglucomutase 2 | –1,251 |
|
| Aryl hydrocarbon receptor nuclear translocator | –1,228 |
|
| BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like | –1,214 |
|
| ruvB-like 2 | –1,212 |
|
| Heat shock protein HSP 90-beta | –1,211 |
|
| Galectin 3 | –1,136 |
|
| Mitogen-activated protein kinase kinase kinase 1 | –1,115 |
|
| Hypoxia inducible factor 1 alpha inhibitor | –1,098 |
|
| Prolyl 4-hydroxylase subunit alpha 1 | –1,081 |
|
| Period circadian protein homolog 1 | –1,064 |
|
| Class E basic helix-loop-helix protein 40 | –1,043 |
|
| Beta-glucuronidase precursor | –1,038 |
|
| Transferrin receptor protein 1 | –1,025 |
|
| Nicotinamide phosphoribosyltransferase | –1,017 |
|
| Cyclin G2 | –1,008 |
Figure 3.Functional meaning of hypoxia signature in uterine expansion and remodeling during pregnancy. (A) Distribution of implicated functions based on KEGG pathways database, where pathways were represented in (y) axis and number of genes belonging to each pathway are detailed in the x axis. Pathways were grouped into four main categories: uterine expansion during pregnancy (green), energy metabolism (yellow), uterine remodeling after pregnancy (pink), and inflammatory response (orange). (B) HIF-1 signaling pathway diagram containing the fold change representation for the 20 genes belonging to this pathway. Other pathways and functions represented by the genes (described in HIF-1 pathway) are shown in the same color that are shown in A section of this figure.
Figure 4.Network modeling of gene expression and functional relationship between uterine processes. Big nodes represent the main functions during the process and small nodes correspond to genes. Edges are linking genes belonging to functions. The model is representing the four designed functions and the genes that are shared by them. Genes in red are upregulated in hypoxia and genes in blue are downregulated in hypoxia. Bold circles are validated genes by RT-qPCR.